April 2026
Psychedelic-assisted therapy
What April 2026's 6 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.
Research published in April 2026 indicates that psychedelic-assisted therapy shows promise for reducing substance misuse and suicidal ideation, with large effect sizes reported for DMT on substance use reduction and consistent reductions in suicidal ideation with ayahuasca in treatment-resistant depression. However, the evidence is limited by high heterogeneity, small sample sizes, and a lack of large-scale longitudinal studies, and findings from adult studies cannot be directly applied to adolescents due to distinct developmental and ethical considerations.
Confidence in the evidence
Low-Moderate- Only one systematic review with meta-analysis (article_id 27274) provides quantitative pooled effects, but it reports high heterogeneity (I²=96.9%) and high risk of bias.
- The systematic review on ayahuasca (article_id 28190) includes only five studies with methodological heterogeneity, limiting generalizability.
- Two studies (article_ids 27801, 32896) are theoretical or conceptual frameworks without empirical data, and one (article_id 27894) is a theory-building synthesis.
- The qualitative study (article_id 27873) has a very small sample (n=7) and relies on therapist reports, which may introduce bias.
- No large-scale RCTs or longitudinal studies are included in the provided evidence, and adolescent-specific data are absent.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders. 2026 | theoretical | Supports | Proposes a conceptual framework for psilocybin-assisted schema therapy for personality disorders, suggesting potential synergies based on predictive coding models. | |
| Ritual in Psychedelic Therapy: A Principle-Based Framework 2026 | theoretical | Unclear | Proposes a principle-based framework for ritual in psychedelic therapy, emphasizing safety, trust, and co-created processes, but does not test efficacy. | |
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Consistently found that ayahuasca administration is associated with rapid and significant reductions in suicidal ideation and depressive symptoms. |
| Adolescent Psychedelic-Assisted Therapy 2026 | theoretical | Unclear | Argues that translating adult psychedelic-assisted therapy to adolescents requires a systems-psychological approach due to age-dependent effects and ethical considerations. | |
| Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis 2026 | systematic review and meta-analysis | Supports | DMT yielded a large overall effect size for substance abuse reduction (g=0.94), with greater effects when combined with psychotherapy (g=1.38) compared to without (g=0.60). | |
| Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes 2026 | qualitative | 7 | Supports | Therapists reported a synergistic relationship between psychedelics and psychotherapy, with psychedelics acting as unspecific catalysts for therapeutic processes. |
Proposes a conceptual framework for psilocybin-assisted schema therapy for personality disorders, suggesting potential synergies based on predictive coding models.
theoretical
Proposes a principle-based framework for ritual in psychedelic therapy, emphasizing safety, trust, and co-created processes, but does not test efficacy.
theoretical
Consistently found that ayahuasca administration is associated with rapid and significant reductions in suicidal ideation and depressive symptoms.
systematic review Sample size: 5
Argues that translating adult psychedelic-assisted therapy to adolescents requires a systems-psychological approach due to age-dependent effects and ethical considerations.
theoretical
DMT yielded a large overall effect size for substance abuse reduction (g=0.94), with greater effects when combined with psychotherapy (g=1.38) compared to without (g=0.60).
systematic review and meta-analysis
Therapists reported a synergistic relationship between psychedelics and psychotherapy, with psychedelics acting as unspecific catalysts for therapeutic processes.
qualitative Sample size: 7
Points of agreement
- Psychedelic-assisted therapy shows potential for reducing symptoms in treatment-resistant conditions (substance misuse, depression with suicidality).
- The psychotherapeutic context (e.g., integration, ritual, therapist support) is considered important for therapeutic outcomes.
- Neuroplasticity and modulation of the default mode network are proposed mechanisms across multiple studies.
Conflicts
- The meta-analysis on DMT (article_id 27274) reports high heterogeneity (I²=96.9%), indicating inconsistent effects across studies.
- The qualitative study (article_id 27873) emphasizes the role of psychotherapy, while the meta-analysis shows larger effects with psychotherapy, but the theoretical papers (article_ids 27801, 27894) focus on frameworks without empirical comparison.
Gaps
- No large-scale, methodologically rigorous longitudinal studies are provided.
- Adolescent-specific empirical data are absent; only theoretical considerations are offered.
- Durability of effects beyond post-treatment is not addressed in the provided studies.
- Blinding and placebo control are not discussed in the included evidence.
- Dose-response relationships and safety profiles are not systematically evaluated.